BiotechTube

SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injections

Phase 1Active
1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypercholesterolemia and Hyperlipidemia

Conditions

Hypercholesterolemia and Hyperlipidemia

Trial Timeline

Mar 14, 2025 → Jul 1, 2025

NCT ID
NCT06837077

About SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injections

SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injections is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Hypercholesterolemia and Hyperlipidemia. The current trial status is active. This product is registered under clinical trial identifier NCT06837077. Target conditions include Hypercholesterolemia and Hyperlipidemia.

What happened to similar drugs?

20 of 20 similar drugs in Hypercholesterolemia and Hyperlipidemia were approved

Approved (20) Terminated (2) Active (0)
✅generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)YuhanApproved
✅Rosuvastatin+Ezetimibe + RosuvastatinYuhanApproved
✅colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved
✅colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved
✅colesevelam HCl + placeboDaiichi SankyoApproved
✅colesevelam HCl tablets, and atorvastatin tablets + colesevelam HCl placebo tablets and atorvastatin tabletsDaiichi SankyoApproved
✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved

Hype Score Breakdown

Clinical
6
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06837077Phase 1Active

Competing Products

20 competing products in Hypercholesterolemia and Hyperlipidemia

See all competitors
ProductCompanyStageHype Score
Evacetrapib + Ezetimibe + Atorvastatin + PlaceboEli LillyPhase 3
32
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)YuhanApproved
43
Rosuvastatin+Ezetimibe + RosuvastatinYuhanApproved
43
colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved
43
colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved
43
colesevelam HCl + placeboDaiichi SankyoApproved
43
Bempedoic acid and/or its fixed-dose combination with ezetimibeDaiichi SankyoPre-clinical
30
colesevelam HCl tablets, and atorvastatin tablets + colesevelam HCl placebo tablets and atorvastatin tabletsDaiichi SankyoApproved
43
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Bempedoic Acid 180Mg/Ezetimibe 10Mg TabDaiichi SankyoPre-clinical
26
Colesevelam Hydrochloride + Ezetimibe + SimvastatinDaiichi SankyoApproved
43
pravastatin tablets and Welchol tablets + pravastatin tablets and Welchol placebo tabletsDaiichi SankyoApproved
43
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
18
atrovastatinAstellas PharmaPre-clinical
26
Pitavastin 4mg + Atorvastatin 20mg + Rosuvastatin 5mgEli LillyApproved
43
PPAR alpha + atorvastatin + placeboEli LillyPhase 2
35
Evacetrapib + PlaceboEli LillyPhase 3
32
LY3015014 + Placebo + Statin + EzetimibeEli LillyPhase 2
35
SHR-1209Jiangsu Hengrui MedicinePhase 2
31
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
40